ANPEP and neoplasm: From our work, going forward, tumour-targeting prodrugs hydrolyzing CD13 should avoid targeting ATM and its downstream targets; not doing so may cause impaired ATM signaling and subsequent reduced CD13 expression, hindering the efficacy of the therapeutic.